PharmaTelevision - NovaQuest: Principles and Strategies

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: NovaQuest: Principles and Strategies

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this exclusive interview, Fintan Walton talks to Ben Cons, Vice President of NovaQuest, about NovaQuest’s functions and operations, and how these differ from those of its parent company, Quintiles Transnational. Ben talks about the financial commitment NovaQuest has made to its partnerships and how this is split between its biotech and large pharma clients. He outlines the two principle ways in which NovaQuest operates with companies, and how it shares some of the risks and returns. Ben discusses the current changes in the industry, the drivers for these changes, and how they affect NovaQuest’s business. He highlights some examples of partnerships that show how the company is adapting to these changes – in particular he discusses its alliances with Eli Lilly and Solvay Pharmaceuticals. Ben talks about how NovaQuest manages the risk within its alliance portfolio and the company’s approach to its equity contributions in life sciences companies. Finally, he gives his opinion on the progress of the industry from NovaQuest’s viewpoint, and discusses how the company will grow in relation to Quintiles.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

NovaQuest's functions and operations, and how these differ from those of its parent company Quintiles Transnational.

Fintan Walton:

Hello and welcome to PharmaVentures Business Review here in London. On this show I have Ben Cons, Vice President at NovaQuest, welcome to the show Ben.

Ben Cons:

Lovely to be here. Thank you Fintan.

Fintan Walton:

Ben, you're part of NovaQuest and NovaQuest is part of Quintiles most people in the pharmaceutical industry will know about Quintiles some of them may have heard about NovaQuest, but NovaQuest's function and its operations although they are associated with Quintiles are quite distinct, so could you tell us a little bit about what actually NovaQuest does?

Ben Cons:

Yeah thanks Fintan, NovaQuest is the managed partnership entity within Quintiles Transnational so we look to design the bespoke solutions to work alongside our pharmaceutical partners using the strength of our core business which is the 20,000 employees within our business providing key for service solutions and in contract research and commercialization.

Fintan Walton:

So in a way then you really what you are offering to pharmaceutical companies and biotech companies is a way to access the skill base the Quintiles has but probably in a different way than they normally would through a fee for service basis?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Ben Cons

Vice President

Ben Cons, PhD, Vice President of NovaQuest, structures and delivers managed partnerships with pharmaceutical and biotechnology companies in Europe and the US. He has participated in tailored financial solutions worth over US$1 B by leveraging the intellectual capital, management and financial resources of NovaQuest and Quintiles. In addition to his role as deal architect, Dr Cons is responsible for delivering the strategic plan for NovaQuest, including relationships with venture capital groups, private equity groups and investment banks. An innovative team leader, he is adept in developing partnership solutions between companies that realize value for all parties. Dr Cons joined Quintiles in 1996, bringing his expertise in pharmaceutical drug development and commercialization to drive corporate development goals. He became a part of the PharmaBio Development Group (NovaQuest's predecessor) in 2003. Early on in his career, Dr Cons expanded his research experience in molecular pharmacology through a position in drug development with Schering AG. Later, at Glaxo Wellcome, he developed expertise in marketing and business development, particularly through a joint venture with Reuters. Educated in the UK, Dr Cons acquired a bachelor's degree in biological sciences with honors from Portsmouth Polytechnic, and then continued his studies to earn a doctorate in molecular pharmacology within the physiology and pharmacology department of Southampton.

NovaQuest

NovaQuest, the strategic partnering group of Quintiles Transnational, is an industry pioneer in offering tailored financial and operational solutions that help pharmaceutical and biotech companies overcome development and commercialization challenges, including leveraging virtual clinical development m odels. Its unique managed-partnership approach ensures sponsorship by senior-level executives; access to global development and commercial resources and expertise; and efficient operational delivery of services. Since 2000, NovaQuest partnerships have committed more than US$2 B in capital to pharmaceutical and biotech companies of all sizes.